See the DrugPatentWatch profile for Datscan
What is DaTSCAN?
DaTSCAN is a single‑photon emission computed tomography (SPECT) tracer that binds to dopamine transporters in the brain, helping clinicians detect dopaminergic deficits in Parkinson’s disease and related disorders. It contains the radioisotope ^123I‑ioflupane and was approved by the U.S. Food and Drug Administration in 2006 [1].
Why a Phase I trial?
Before a drug can be marketed, a Phase I study confirms that the tracer is safe, that it behaves predictably in the body, and that the chosen dose gives reliable imaging. For DaTSCAN, the Phase I study focused on healthy volunteers to assess radiation exposure, metabolic stability, and potential adverse events [2].
Who can enroll in a DaTSCAN Phase I study?
Participants are typically adults who are otherwise healthy, with no significant medical history, and not taking medications that would interfere with dopamine transporters. They must also understand the risks of radiation exposure and sign an informed‑consent form that explains the investigational nature of the tracer [2].
What does the study design look like?
The protocol is a single‑dose, open‑label, non‑randomized trial. Volunteers receive a calculated amount of ^123I‑ioflupane, then undergo SPECT imaging at several time points to measure uptake and clearance. Blood and urine samples track how the tracer is metabolized and excreted. The study also monitors vital signs, laboratory values, and any side effects for up to 30 days after injection [2].
Which safety signals are monitored?
Because the tracer contains ionizing radiation, the primary safety concern is cumulative radiation dose. Secondary concerns include allergic reactions to the radiopharmaceutical and transient changes in neurological status. All events are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) [3].
How do researchers evaluate the tracer’s performance?
The key endpoint is “image quality,” defined by the contrast between the striatum and surrounding brain tissue. Secondary endpoints include the half‑life of the tracer in the bloodstream, the percentage of the dose excreted unchanged in urine, and any correlation between dose and image resolution. A successful Phase I result is a clear safety profile and a dose that yields high‑contrast images with acceptable radiation burden [2].
What does the Phase I data tell us about future studies?
Positive Phase I results allow investigators to design Phase II trials that recruit patients with Parkinsonian syndromes. These later studies test diagnostic accuracy, compare DaTSCAN to clinical criteria, and assess whether the tracer can guide treatment decisions. If Phase I data reveal unforeseen toxicity, the development program may stall or require dose adjustment [4].
How does DaTSCAN compare to other dopamine‑transport imaging agents?
Other tracers, such as ^18F‑FDOPA PET and ^11C‑CFT PET, also target the dopamine system. DaTSCAN’s advantage is its availability in most nuclear‑medicine departments due to the long half‑life of ^123I and the relative simplicity of SPECT equipment. However, PET tracers provide higher spatial resolution and quantitative uptake values. The choice depends on clinical need, equipment, and regulatory approval in the region [5].
When might we see new data from DaTSCAN research?
The most recent Phase I publication dates to 2012, with subsequent Phase II and III studies completing around 2015. Updated safety and efficacy data are often released in peer‑reviewed journals or presented at neurology conferences every few years. Patients and clinicians can check clinicaltrials.gov for ongoing studies and FDA’s drug‑approval updates for new indications or labeling changes [6].
What if the Phase I trial fails?
A failure could stem from unacceptable radiation dose, adverse reactions, or inadequate image contrast. In such a scenario, the sponsor might reduce the dose, adjust the formulation, or abandon the program. Alternatively, the data could shift focus to a different radiopharmaceutical or a new indication that requires less radiation exposure [4].
What should patients consider before participating in a DaTSCAN study?
Patients should discuss the risk of radiation with their physician, confirm they are not pregnant, and understand that participation is voluntary and does not guarantee treatment benefits. The trial’s informed‑consent form will detail the potential for minor discomfort and the lack of guaranteed diagnostic improvement compared to standard care [2].
Where can I find the original Phase I study details?
The primary publication is available in the Journal of Nuclear Medicine (2012) and is indexed on PubMed. The trial registration on ClinicalTrials.gov (NCT00483755) provides full protocol details, inclusion criteria, and timelines. The FDA’s drug‑approval database also lists the official labeling and safety summary for DaTSCAN [1][2][6].
---
Sources
[1] FDA, “DaTSCAN – Post‑market drug safety communications.” https://www.fda.gov/drugs/postmarket-drug-safety-communications/datscan
[2] ClinicalTrials.gov, “Phase I Study of 123I‑Ioflupane (DaTSCAN) in Healthy Volunteers.” https://clinicaltrials.gov/ct2/show/NCT00483755
[3] U.S. National Institutes of Health, “Common Terminology Criteria for Ad